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Statins possess potent immunomodulatory effects that may play a role in preventing acute graft-versus-host
disease (aGVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). We performed a phase II
study of atorvastatin for aGVHD prophylaxis when given to allo-HCT recipients and their HLA-matched sibling
donors. Atorvastatin (40 mg/day) was administered to sibling donors, beginning 14 days before the antici-
pated start of stem cell collection. Allo-HCT recipients (n ¼ 40) received atorvastatin (40 mg/day) in addition
to standard aGVHD prophylaxis. The primary endpoint was cumulative incidence of grades II to IV aGVHD at
day 100. Atorvastatin was well tolerated, with no attributable grades III to IV toxicities in donors or their
recipients. Day 100 and 180 cumulative incidences of grades II to IV aGVHD were 30% (95% conﬁdence interval
[CI], 17% to 45%) and 40% (95% CI, 25% to 55%), respectively. One-year cumulative incidence of chronic GVHD
was 43% (95% CI, 32% to 69%). One-year nonrelapse mortality and relapse incidences were 5.5% (95% CI, .9% to
16.5%) and 38% (95% CI, 18% to 47%), respectively. One-year progression-free and overall survival rates were
54% (95% CI, 38% to 71%) and 82% (95% CI, 69% to 94%). One-year GVHD-free, relapse-free survival was 27%
(95% CI, 16% to 47%). These results did not differ from our historical control subjects (n ¼ 96). Although safe
and tolerable, the addition of atorvastatin did not appear to provide any beneﬁt to standard GVHD prophy-
laxis alone.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) is the major
complication of allogeneic hematopoietic cell trans-
plantation (allo-HCT), developing in 30% to 50% of patients
undergoing a matched related or unrelated allo-HCT
following standard aGVHD prophylaxis [1-3]. Thedgments on page 79.
equests: Yvonne A. Efebera, Division of
rsity Comprehensive Cancer Center, The
OH 43210.
@osumc.edu (Y.A. Efebera).
15.07.034
ty for Blood and Marrow Transplantation.pathophysiology of aGVHD is complex but involves the
activation of host antigen-presenting cells by recipient con-
ditioning, which in turn activate transplanted donor T lym-
phocytes that expand and differentiate into effector cells that
mediate cytotoxicity against recipient tissues through
FaseFas ligand interactions, perforinegranzyme B, and
cytokine production [1,3-5]. When severe, aGVHD carries a
poor prognosis, with rates of long-term survival of only 25%
for grade III and 5% for grade IV [2].
HMG-CoA reductase inhibitors (statins), the cholesterol-
lowering medications, exhibit a variety of immunomodula-
tory and anti-inﬂammatory properties that are relevant in
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by statins not only inhibits the synthesis of cholesterol but
also that of key isoprenoid intermediate molecules required
for the isoprenylation of GTP-binding cell signaling proteins
such as Ras, Rho, and Rac [7]. Inhibiting Ras leads to devel-
opment of Th 2 cells and regulatory T cells (Tregs) [8] while
inhibiting pro-inﬂammatory Th 1 driven responses [9,10].
Statins also indirectly decrease T cell activation by reducing
the expression of CD80 and CD86, inhibiting the proliferation
of alloreactive T cells in response to simvastatin-treated
CD40-activated B cells [11].
In an MHC mismatched murine model, simultaneous
administration of atorvastatin to both donor and recipient
mice showed protective effects against aGVHD when
compared with treatment of donor or recipient alone due to
the reduction of Th 1 cytokines, proliferation of Th 2 cyto-
kines, and down-regulation of costimulatory molecules and
MHC-II expression on antigen-presenting cells [12]. Recently,
a single-institution prospective phase II clinical study used
the same strategy as in the mouse model (atorvastatin given
to donors and recipient) and showed an impressive 3.3%
cumulative incidence of aGVHD at day 100 in patients un-
dergoing sibling-matched allo-HCT [13]. We now present the
results of a phase II prospective trial evaluating the safety
and efﬁcacy of atorvastatin for the prophylaxis of aGVHD in
patients undergoing HLA-matched related donor allo-HCT at
our institution, with inclusion/exclusion criteria and treat-
ment plan virtually identical to the above study.
METHODS
The study was approved by the Institutional Review Board of the Ohio
State University. Written informed consent was obtained from both donor
and patient before enrollment. The study was listed in clinicaltrials.gov
(NCT01491958).
Inclusion and Exclusion Criteria
Patients aged 18 years with hematologic malignancies requiring a
myeloablative (MA) or reduced-intensity conditioning allo-HCT who had
an HLA-matched (10/10 HLA-A, -B, -C, -DQ, and -DRB1 matched by high
resolution) sibling donor were eligible. Donors and patients were required
to have a Karnofsky performance status 70; adequate renal function
(creatinine clearance 40% of normal); bilirubin, aspartate aminotrans-
ferase, and alanine aminotransferase <2 times the upper limit of normal;
and no other serious organ dysfunction or medical conditions. Ex vivo or
in vivo T celledepleted allo-HCT, including antithymocyte globulin, were
excluded.
GVHD Prophylaxis and Conditioning Regimen
Consenting donors received atorvastatin 40 mg/day orally starting
at least 14 days before the anticipated ﬁrst day of peripheral blood stem
cell (PBSC) collection via leukapheresis until a target CD34þ cell dose of
4  106/kg recipient weight was reached. Donor stem cells were mobilized
with ﬁlgrastim (10 mg/kg/day) and infused fresh into patients. Recipients
were given atorvastatin 40 mg/day orally starting at least 7 days before
initiation of transplant conditioning. In addition, patients uniformly
received our standard prophylaxis GVHD regimen of methotrexate (15 mg/
m2 on day þ1 after stem cell infusion and 10 mg/m2 on days þ 3, þ6,
and þ11 for MA and 5 mg/m2 on days þ1, þ3, and þ6 for reduced-intensity
conditioning allo-HCT) and tacrolimus (.02 mg/kg every 24 hours as a
continuous i.v. infusion or .03 mg/kg orally beginning on day e2, adjusted
to target dose level of 8 to 12 ng/mL). Atorvastatin was continued until
day þ180, or until cessation of immunosuppression, signiﬁcant toxicity,
grades II to IV aGVHD, or severe chronic GVHD (cGVHD). Fungal, viral, and
Pneumocystic jiroveci prophylaxis were routinely instituted. Granulocyte
colony-stimulating factor was only used in cases of infections with
neutropenia.
Endpoints
Primary outcomes were incidence of grades II to IV aGVHD at day þ100
and safety of atorvastatin administration in both donor and recipient. Sec-
ondary outcomes included rates of late-onset aGVHD (days þ101 to þ180),
cGVHD, disease relapse, nonrelapse mortality (NRM), progression-freesurvival (PFS), and overall survival (OS). Grading of aGVHD and cGVHDwere
done using the Consensus Conference criteria [14] and the National In-
stitutes of Health Consensus Development Project Criteria [15,16], respec-
tively. Although not required, the diagnosis of aGVHD was histologically
conﬁrmed whenever possible. Compliance with atorvastatin among donors
and patients was monitored by reviewing diaries and assessing pill bottles.
Adverse events and toxicities in both donors and patients were monitored
using the National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE) V 4.0 criteria (http://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Donor Cell Chimerism, Immune Reconstitution, and Cytokine Analysis
Lineage-speciﬁc (myeloid [CD33þ] and T lymphoid [CD3þ]) donor cell
chimerism analysis was performed on days þ30, þ100, þ180, and þ365
after allo-HCT. For immune reconstitution assays, detailed ﬂow cyto-
metric analysis of B and T lymphocytes and natural killer (NK) cells were
performed on allograft samples (day 0) and PB collected on days þ30
and þ 100 (details in Supplementary Table 1). For cytokine analysis, PB
was collected from patients before start of the conditioning regimen and
on days 0 (allograft infusion day), þ30, and þ100 after allo-HCT. Plasma
was extracted and levels of 27 cytokines measured (details available in
online supplementary data).
Statistical Analysis
We used Simon’s mini-max 2-stage design to assess if the use of ator-
vastatin reduced the incidence of grades II to IV aGVHD at day þ100. Our
hypothesis was that the use of atorvastatin would reduce the proportion of
patients with grades II to IV aGVHD at day þ100 from 35% to 15% (90%
power, a ¼ .05, details available in online supplementary data). Time to
neutrophil engraftment was calculated based on an absolute neutrophil
count.5 109/L for 3 days, and platelet engraftment was based on platelet
count 20  109/L for 7 days without transfusion. PFS and OS were each
deﬁned from the time of transplant, and these estimates were calculated by
the Kaplan-Meier method and compared using the log-rank test.
Cumulative incidence of aGVHD was evaluated within the ﬁrst 180 days
post-transplant, whereas cGVHD was evaluated within the ﬁrst 12 months
post-transplant given that patients were followed for at least 100 days and
without early progression or death. aGVHD was deﬁned as GVHD occurring
within the ﬁrst 100 days of allo-HCT, and late aGVHD was deﬁned as
occurring after day 100 post-transplant. Cumulative incidence of aGVHD,
cGVHD, relapse, and NRM were analyzed using Gray’s test and accounting
for competing risks; competing risks for aGVHD and cGVHDwere relapse or
death, the competing risk for relapse was death from any cause, and the
competing risk for NRM was death due to disease.
For all analyses, patients without an eventwere censored at the time last
evaluated for a particular endpoint. McNemar’s test was used to evaluate
agreement between paired reviewers for GVHD incidence and grading. All
P values presented are from 2-sided tests, where statistical signiﬁcance was
determined at a ¼ .05. All analyses were conducted using SAS software
version 9.3 (SAS Institute, Cary, NC) or the cmprsk package in R, version
2.15.0 (http://www.r-project.org).
Comparison Control Cohort
For historical context, we compared our deﬁned endpoints between
patients on this trial with patients undergoing a 10/10 HLA -matched sibling
PB allo-HCT where neither the patient nor the matched donor received
cholesterol-lowering medications. Between August 2006 and February
2012, the time period consistent with current protocols for transplant and
prophylaxis, 96 patients and donors who had provided consent for data
collection were identiﬁed.
RESULTS
Patient Characteristics
Forty patientedonor pairs were enrolled between March
2012 and January 2014. All patients received PBSC from a
10/10 HLA-matched sibling donors. Patient and donor base-
line characteristics are listed in Table 1. The median age of
patients was 51 years (range, 27 to 71) and of donors 50 years
(range, 25 to 68). Five patients (13%) and 14 donors (35%)
were receiving some form of statin medication before
enrollment that was discontinued and switched to atorvas-
tatin 40 mg at study initiation. Intermediate/high-risk dis-
ease constituted 23 patients (57.5%) by American Society of
Blood and Marrow Transplantation criteria [17] and 36 pa-
tients (90%) by the Disease Risk Index [18]. Twelve patients
Table 1
Baseline Patient Characteristics (N ¼ 40) at the Time of Transplantation
Characteristic Value
Median patient age at transplant, yr (range) 51 (27-71)
Patient sex
Male 20 (50)
Female 20 (50)
Median donor age at transplant, yr (range) 50 (25-68)
Donor sex
Male 20 (50)
Female 20 (50)
Donorepatient sex
MeF 9 (23)
FeM 9 (23)
Match 22 (50)
Diagnosis
ALL 6 (15)
AML 13 (33)
CML 3 (8)
MDS/CMML 7 (18)
Non-Hodgkin/Hodgkin lymphoma 6 (15)
Other 5 (13)
ASBMT risk category [17]
Low 15 (37.5)
Intermediate 12 (30)
High 11 (27.5)
Other 2 (5)
Disease Risk Index [18]
Low 4 (10)
Intermediate 23 (57.5)
High 11 (27.5)
Very high 2 (5)
Karnofsky performance score
Median (range) 90 (70-100)
100 5 (13)
90 26 (65)
80 5 (13)
70 4 (10)
Comorbidity index score
Median (range) 3 (0-8)
0 3 (8)
1-2 16 (40)
3-4 17 (43)
5þ 4 (10)
Conditioning regimen and type
MA 12 (30)
Fludarabine/busulfan 6
Total body irradiation/etoposide 4
Total body irradiation/cyclophosphamide 2
Reduced-Intensity Conditioning 28 (70)
Fludarabine/busulfan 26
Fludarabine/melphalan 2
Patient prior statin use
Yes 5 (13)
No 35 (88)
Donor prior statin use
Yes 14 (35)
No 26 (65)
HLA match (high resolution)
10/10 40 (100)
Donor stem cell source
PB 40 (100)
ABO mismatch
Yes 14 (35)
No 26 (65)
EBV seropositivity match at screening (donor/recipient)
EBV/EBVþ 5 (13)
EBV/EBV 1 (3)
EBVþ/EBV 2 (5)
EBVþ/EBVþ 32 (80)
CMV seropositivity match at screening (donor/recipient)
CMV/CMVþ 6 (15)
CMV/CMV 18 (45)
CMVþ/CMV 6 (15)
CMVþ/CMVþ 10 (25)
(Continued)
Table 1
(continued)
Characteristic Value
Prior autologous HCT
Yes 5 (13)
No 35 (88)
Remission status at transplant
CR 26 (65)
PR 5 (12.5)
PD 0
Other* 9 (22.5)
Stem cell mobilization
Granulocyte colony-stimulating factor 40 (100)
CD34þ cell  106 infused
Median 5.90
Range 2.20-15.02
CD3þ cells  108 infused
Median 2.65
Range 1.14-7.29
ALL indicates acute lymphocytic leukemia; AML, acute myelogenous leu-
kemia; CML, chronic myelogenous leukemia; ASBMT, American Society of
Blood and Marrow Transplantation; PB, peripheral blood; ABO, A, B and O
blood types; EBV, Epstein-Barr virus; CR, complete remission; PR, partial
remission; PD, progression of disease.
Values are number of cases with percents in parentheses, unless otherwise
noted.
* Two chronic phase myelogenous leukemia, 3 CMML, 1 myeloﬁbrosis,
1 MDS, 1 each chemosensitive Hodgkin and non-Hodgkin lymphoma.
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were sex-mismatched. Sixty-ﬁve percent of patients were in
complete remission and 12.5% in partial remission at the
time of transplant.Compliance and Toxicity
Atorvastatin was generally well tolerated by donors,
with no more than grade 2 toxicity attributable to atorvas-
tatin observed. The median duration of atorvastatin use in
donors was 14 days (range, 13 to 27). Seventeen donors (43%)
received atorvastatin for more than 14 days. Atorvastatinwas
held for 2 days in 1 donor 16 days after starting the drug
because of grade 2 myalgia. The drug was restarted at 20 mg
for 5 more days without any further toxicity. Atorvastatin did
not adversely affect stem cell collection, with a median
CD34þ collection of 5.9  106/kg (range, 2.2 to 15.02) and
median collection day of 1 (range, 1 to 3).
Patients received atorvastatin for a median of 127 days
(range, 32 to 287). Atorvastatin was held in 5 patients,
temporarily in 4. One patient developed posterior reversible
encephalopathic syndrome on day 24 post-transplant.
Atorvastatin was held for 7 days and restarted at full dose
for a total use of 196 days. Two patients had grade 2 elevated
liver enzymes for which atorvastatin was held brieﬂy and
restarted at full dose for a total use of 126 and 285 days,
respectively. One patient relapsed just before conditioning
after 7 days of atorvastatin. After achieving a second complete
remission, atorvastatin was restarted and given for a total of
196days. Theﬁfth patient had grade 4 asymptomatic elevated
liver enzymes with normal bilirubin after being on atorvas-
tatin for 146 days. A liver biopsy showed mixed portal and
lobular inﬂammation with a range of differential diagnoses,
including medications and infections. The patient did not
receive steroids and had no evidence of aGVHD. None of these
was attributable to atorvastatin by the treating physician. No
other toxicities were attributable to atorvastatin.
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The median time to neutrophil and platelet engraftment
were 18 days (range, 13 to 26) and 14 days (range, 9 to 29),
respectively. Median myeloid cell donor chimerism was
100% at all time points analyzed. Median T cell chimerism
was 100% from day þ180 onward (Supplementary Table 2).
Primary or secondary graft failure did not occur.
Graft-versus-Host Disease
All patients were assessable for aGVHD. Two patients
developed grade I aGVHD of the skin and were treated
with topical steroids. The cumulative incidences of grades II
to IV aGVHD at days þ100 and þ 180 were 30% (95% conﬁ-
dence interval [CI], 17% to 45%) and 40% (95% CI, 25% to 55%),
respectively. Corresponding incidence of grades III to IV
aGVHDwas 8% (95% CI, 1.9 to 18.4%) at both 100 and 180 days
(Figure 1A). The median day of onset of aGVHD was 42
(range, 17 to 172). Six of 12 patients with aGVHD had at least
2 organs involved. Although not required, the diagnosis
of aGVHD was histologically conﬁrmed whenever possible.
All patients except 4 (2 with upper gastrointestinal [UGI]
and 2 with skin involvement) had histologic conﬁrmation
or evidence of aGVHD. All patients with suspected lower
gastrointestinal GVHD had histologic conﬁrmation with
assessment for cytomegalovirus (CMV) and adenovirus
infection. CMV and adenovirus were negative in all biopsy
samples.
No patient was tapered off tacrolimus before day 100
unless relapse or toxicity was noted. Only 1 patient was
taken off tacrolimus before day 100 because of renal toxicity
and started on mycophenolate. Four patients developed
aGVHD after day 100. The ﬁrst patient who developed skin
aGVHD at day 141 did not take tacrolimus for 3 to 4 daysFigure 1. aGVHD prophylaxis with atorvastatin. (A) Cumulative incidences of aGVHD
severe. (C) Cumulative incidences of NRM and relapse. (D) PFS and OS curves.before onset of GVHD. A second patient had persistent
cytogenetic abnormality post-HCT evaluation (day 100) for
myelodysplastic syndrome (MDS) and tacrolimus was
tapered off. The patient developed aGVHD 2 months later
(day 165) initially with skin and then lower gastrointestinal
involvement. The third patient who had diffuse large B cell
lymphoma and had persistent disease at transplant was
taken off immune suppression at day 105 and developed skin
GVHD on day 115. The fourth patient was taken off tacroli-
mus on day 77 because of worsening renal insufﬁciency.
Mycophenolatewas started on the same day, and aGVHDwas
diagnosed on day 108 with nausea/vomiting and weight loss.
The cumulative incidence of cGVHD at 1 year was 43%
(95% CI, 32% to 69%). The distribution of organ involvement is
listed in Table 2. Cumulative incidences of mild and moder-
ate/severe cGVHD were 23.6% (95% CI, 10.7% to 39.5%) and
28.2% (95% CI, 12.8% to 45.9%), respectively, and of limited
and extensive cGVHD were 19% (95% CI, 8.71% to 36.1%) and
25% (95% CI, 15% to 48.9%), respectively (Figure 1B, Table 3).
To mitigate any biases in GVHD grading due to lack of
blinding, 4 authors performed a retrospective review of
patient charts and assigned GVHD grades without knowl-
edge of the original assessment. There was good concor-
dance between the original GVHD grading and that of the
independent reviewers for aGVHD (P ¼ .5637) and cGVHD
(P ¼ .3173) with some minor discordance for late aGVHD
(P ¼ .0833) (Table 4).
Relapse and Survival
The median follow-up of surviving patients was
13 months (range, 2.2 to 28.5), where 11 patients (27.5%)
died, 8 from relapsed disease, 2 from complications of GVHD,
and 1 from respiratory failure (Supplementary Table 3). One-grades II-IV and III-IV. (B) Cumulative incidences of cGVHD, mild/moderate and
Table 2
Organ Involvement in cGVHD for Statin Patients (N ¼ 17)
Organ Involvement Number of Patients
Oral 13 (76%)
Skin 6 (35%)
Liver 3 (18%)
Eyes 3 (18%)
Lungs 3 (18%)
Genital 2 (12%)
Two or more organs involved 9 (53%)
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were 5.5% (95% CI, .9% to 16.5%) and 32% (95% CI, 18% to 47%),
respectively (Figure 1C). One-year rates of PFS and OS were
54% (95% CI, 38% to 71%) and 82% (95% CI, 69% to 94%),
respectively (Figure 1D). The one-year rate of GVHD-free,
relapse-free survival (GRFS) was 27% (95% CI, 16% to 47%)
(Figure 2). GFRS events were deﬁned as grades III to IV
aGVHD, cGVHD requiring systemic immune suppressive
treatment, disease relapse, or death from any cause during
the ﬁrst 12 months after allo-HCT [19].Comparison with Control Cohort
The intensity of conditioning regimen, patient age, and
donor sex were all evaluated and found to be comparable
between the study patients and the historical control cohort
(nonstatin group, Supplementary Table 4). aGVHDTable 3
Pattern of GVHD of Statin vs. Nonstatin Group
GVHD Assessment
Cumulative incidence: aGVHD
Grades II-IV, day 100
Number of events
Cumulative incidence at day 100 (95% CI)
Grades III-IV, day 100
Number of events
Cumulative incidence at day 100 (95% CI)
Grades II-IV, day 180
Number of events
Cumulative incidence at day 180 (95% CI)
Grades III-IV, day 180
Number of events
Cumulative incidence at day 180 (95% CI)
Cumulative incidence: cGVHD
Any cGVHD
Number of events
Cumulative incidence at 12 months (95% CI)
Extensive cGVHD
Number of events
Cumulative incidence at 12 months (95% CI)
Severe cGVHD
Number of events
Cumulative incidence at 12 months (95% CI)
Limited vs. extensive cGVHD
Number assessable
Number of events
Limited
Extensive
Estimated cumulative incidence of limited cGVHD at 12 months (95% CI)
Estimated cumulative incidence of extensive cGVHD at 12 months (95% CI)
Mild vs. mod/severe cGVHD
Number assessable
Number of events
Mild
Moderate/severe
Estimated cumulative incidence of mild cGVHD at 12 months (95% CI)
Estimated cumulative incidence of mod/severe cGVHD at 12 months (95% C
Values in parentheses are percents or 95% CIs.prophylaxis in control subjects consisted of methotrexate/
tacrolimus only, and neither patients nor their corresponding
donors had been exposed to cholesterol-lowering medica-
tions. Signiﬁcant differences between atorvastatin and non-
statin patients included a higher number of MDS/chronic
myelomonocytic leukemia (CMML) patients (P ¼ .0374) and
increased use of ﬂudarabine/busulfan conditioning regimen
in the statin group (P ¼ .0288) (Supplementary Table 4).
Donor cell chimerism (Supplementary Table 2) as well as
CMV and Epstein-Barr virus reactivation, BK viremia, and
fungal or bacterial infections (Supplementary Table 5) were
not signiﬁcantly different between groups. Moreover, we did
not ﬁnd any signiﬁcant differences in the incidence rates of
aGVHD (P ¼ .8303), cGVHD (P ¼ .915), relapse (P ¼ .4311), PFS
(P¼ .2862), OS (P¼ .098), and GFRS (P¼ .84) (Figures 2, 3, and
4; Table 3; Supplementary Table 3).
We analyzed the PBSC allograft (day 0) and PB samples at
days þ30 and þ100 of statin patients compared with 25
nonstatin patients to determine the effect of atorvastatin on
allograft composition and immune reconstitution. The
statin group allografts contained less NK cells and Tregs
than the nonstatin group. This reduction in NK cells and
Tregs appeared to affect the reconstitution of these subsets
post-transplant as reﬂected by their continued decrease on
days 30 and 100 post-transplant compared with the non-
statin group (Table 5). Cytokine analysis performed on 20
statin and 16 nonstatin patients matched to age, condi-
tioning regimen, and evidence/no evidence of GVHD foundStatin Group (n ¼ 40) Nonstatin Group (n ¼ 96) P
12 (30) 27 (28) .83
.30 (.17-.45) .28 (.20-.37)
3 (8) 9 (9) .78
.075 (.019-.184) .094 (.046-.163)
16 (40) 30 (31) .38
.40 (.25-.55) .31 (.22-.41)
3 (8) 6 (6) .75
.075 (.019-.184) .0625 (.025-.123)
17 (43) 46 (48)
.52 (.32-.69) .50 (.39-.60) .91
10 (25) 44 (46)
.31 (.15-.48) .48 (.36-.58) .0495
5 (13) 11 (11)
.15 (.05-.29) .13 (.07-.22) .91
37 83
7 (19) 2 (2)
10 (27) 44 (53)
.207 (.087-.361) .024 (.005-.078) .0008
.312 (.15-.489) .476 (.363-.58) .065
37 83
8 (22) 6 (7)
9 (24) 20 (24)
.236 (.107-.395) .074 (.03-.146) .008
I) .282 (.128-.459) .221 (.137-.317) .75
Table 4
Concordance between Original GVHD Grading and Independent Review of
Statin Group
Original Independent Review Totals McNemar’s
aGVHD Grade 0 or 1 Grade2þ .5637
Grade 0 or 1 26 2 28
Grade 2þ 1 11 12
Totals 27 13 40
Late aGVHD Grade 0 or 1 Grade2þ .0833
Grade 0 or 1 32 0 32
Grade 2þ 3 5 8
Totals 35 5 40
cGVHD Extensive Limited .3173
Extensive 11 0 11
Limited 1 5 6
Totals 12 5 17
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with the exception of RANTES (CCR1/CCR5) (Supplementary
Figure 1).
DISCUSSION
Although atorvastatin was well tolerated by donors and
patients, we did not observe any reduction in the incidence
of grades II to IV aGVHD compared with similar historical
control subjects treated at our institution, with a 30% inci-
dence of aGVHD at day þ100 compared with 28% in control
subjects. Moreover, we did not observe any differences in the
incidence of cGVHD, relapse, PFS, OS, and GRFS between
these groups. Our GRFS, a new composite endpoint, was
similar to that reported by the Blood and Marrow Transplant
Clinical Trials Network and others [19]. Although a statisti-
cally signiﬁcant difference was not found, there was a trend
toward decreased NRM (1-year cumulative, 5.5% versus
14.7%; P ¼ .2217) and improved OS (1-year cumulative, 82%
versus 58%) for the atorvastatin group compared with the
control group. The reasons for the differences are not very
apparent except that signiﬁcant differences between ator-
vastatin and nonstatin patients included a higher number of
MDS/CMML patients (P ¼ .0374), an increased use of ﬂudar-
abine/busulfan conditioning regimen, and a decreased use of
cyclophosphamide-based conditioning regimen in the statin
group (P¼ .0288). The MDS/CMML patients mostly fell under
the Center for International Blood and Marrow TransplantFigure 2. Composite GRFS of atorvastatin compared with nonstatin group (conResearch intermediate-risk category. Whether atorvastatin
itself has any effect on NRM and OS is very difﬁcult to address
without a randomized control study using the same condi-
tioning regimen for speciﬁc disease groups.
Our results contrast with those reported by the West
Virginia University (WVU) group, who observed an encour-
agingly low rate of grades II to IV aGVHD of only 3.3% [13].
The reasons for these differences are not immediately
apparent. Contributing factors can only be tested by a
randomized multicenter control trial. Both studies used
identical treatment plans, inclusion/exclusion criteria, and
donorerecipient match and the same dose of atorvastatin
and standard GVHD prophylactic drugs, doses, and schedule.
There were no differences in the median age of patients (51
in our study versus 54) or donors (50 in our study versus
52.5), female donor to male recipient (23% in our study
versus 30%), allograft source, and duration of donor ator-
vastatin use. Although 30% of our patients and 43.2% of the
WVU patients received a MA conditioning regimen, half of
the MA patients in our study received total body irradiation
compared with none in theWVU study; in some studies total
body irradiation is a risk factor for aGVHD [20,21]. A poten-
tially important difference in the 2 studies was the duration
of patient atorvastatin use (median of 127 days in our study
compared with 192 days). However, considering the primary
objective in both studies was the incidence of aGVHD at
day þ100, duration of exposure alone should not explain
these differences. Caveats apply to the interpretation of the
results of both studies, given the single-center nature and
degree of subjectivity inherent in grading grade II aGVHD in
an open-label study. We attempted to mitigate this bias by
having the ﬁnal grading of aGVHD made by 4 independent
reviewers, but bias may still be a factor. The 1-year cumu-
lative incidence of moderate/severe cGVHD did not seem to
be different between the 2 studies (43.5% [95% CI, 20.7% to
64.4%] versus 28.2% [95% CI, 12.8% to 45.9%] in our study),
with a total cGVHD occurrence of 13 and 17 patients (43%
each), respectively.
The rationale for using atorvastatin 40 mg rather than a
higher dose was that in healthy volunteers the plasma
pharmacokinetics of atorvastatin (area under the curve and
maximum concentration) becomes nonlinear and similar at
doses of 40 mg or above [22]. In addition, any potential effecttrol). Dashed line represents statin group and solid line nonstatin group.
Figure 3. aGVHD prophylaxis with atorvastatin compared with nonstatin group (control). (A) Cumulative incidences of aGVHD grades II-IV. (B) Cumulative incidences
of aGVHD grades III-IV. (C) Cumulative incidence of cGVHD, mild/moderate. (D) Cumulative incidence of cGVHD severe. Dashed line represents statin group and solid
line nonstatin group.
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tacrolimus and methotrexate was thought to be lower with
40 mg than with 80 mg.
An area of discussion is in the assessment of grade II
aGVHD and in particular the scoring of isolated UGI symp-
toms. Should grade II GVHD be treated differently from
grades III and IV? Does isolated UGI GVHD exist? Nine of 12
patients (75%) with day þ100 aGVHD were grade II, and 5
patients had isolated UGI symptoms for which high-dose
steroids (at least 1 mg/kg/day prednisone or equivalent)
were instituted for aGVHD. Three of the 5 UGI patients had
endoscopy that showed rare apoptotic cells that could
represent aGVHD. The other 2 patients did not have endos-
copy because they were admitted on the weekend and
symptoms resolved before endoscopy could be done.
A retrospective analysis of 1723 patients by MacMillan
et al. [23] showed an isolated UGI aGVHD of 6.7%. There are
several differences between Macmillan et al.’s study and our
study. First, MacMillan et al. is a retrospective study and
aGVHD patients were selected if they had received predni-
sone 2 mg/kg/day or equivalent i.v. methylprednisolone
compared with ours and conventional use of prednisone
1 mg/kg/day or greater. Second, almost 25% of patients in the
Macmillan study were children, who have completely
different symptom thresholds. A prospective study byWakui
et al. [24] showed that 7 of 19 patients (37%) with conﬁrmed
UGI aGVHD had no other organ involvement, and this was
much higher than the 14% noted in their retrospective
analysis, thus stressing the need for a larger multicenter
prospective study. The development of biomarkers that mayhelp us understand and guide us in the clinical diagnosis and
management of aGVHD are being studied in our institution
as well as many others and should be of considerable beneﬁt
[25-27]. Standardized monitoring of symptoms, with early
review and adjudication of GVHD, has led to improved ac-
curacy of aGVHD staging among some centers [28].
In 1 large retrospective study, statin usewas only effective
when combined with cyclosporine as GVHD prophylaxis
[29]. In this analysis, patients who received cyclosporine as
GVHD prophylaxis and whose donors were on a statin
(n ¼ 54) had a reduced incidence of grades III to IV aGVHD
comparedwith nonstatin patients/donors (n¼ 417, P¼ .003);
however, this effect was not seen in the tacrolimus group
(P ¼ .44) [29]. The limitation of this study was the small
number of statin donors whose recipient received tacrolimus
(n ¼ 21). Our initial retrospective analysis found a positive
correlation with statin use and aGVHD reduction in tacroli-
mus recipients, prompting us to pursue this study using
tacrolimus-based aGVHD prophylaxis [30]. Our current
ﬁndings correlate with those of Rotta et al. [29].
The statin-treated allografts contained less NK cells and
Tregs compared with the nonstatin group. However, this did
not translate into an overall higher rate or severity of aGVHD
and cGVHD as has been described by others [31,32]. The
statin group did have a higher incidence of mild/moderate
cGVHD (P ¼ .0173), but this did not translate to increased
infections or mortality. Further analysis of the signiﬁcance of
these differences is ongoing.
We found no effect of atorvastatin on 26 cytokines,
speciﬁcally IFN-g, tumor necrosis factor-a, IL-2, IL-4, and
Figure 4. aGVHD prophylaxis with atorvastatin compared with nonstatin group (control). (A) Cumulative incidences of NRM. (B) Cumulative incidences of relapse.
(C) PFS curve. (D) OS curves. Dashed line represents statin group and solid line nonstatin group.
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statin. IFN-g, tumor necrosis factor-a, and IL-2 are pro-
inﬂammatory cytokines, the elevation of which is associ-
ated with GVHD [33,34], whereas IL-4 and IL-10 are Th 2
driven anti-inﬂammatory cytokines proTregs, associated
with reduced GVHD [35-37]. We found a marked elevation of
RANTES in statin patients compared with nonstatin patients
(P < .0001). RANTES elevation and polymorphism, through
binding with chemokine CCR1, has been shown to beTable 5
Immune Reconstitution Analysis Statin vs. Nonstatin Group
Marker Allograft Statin (n ¼ 4
Day 0
CD3/CD5616þ (NK cell) 8.00 (2.30-
CD3þ/CD134þ (midactivation T cell) 1.40 (.30-8
CD3þ/CD86þ (activation molecule) .20 (.05-.5
CD4þ/CD25þ/CD127 (Tregs) .10 (0-1.6
CD4þ/CD25þ/CD127ALT (Tregs) .25 (0-1.2
CD3/CD5616þ/CD158 bþ (NK cell) 1.70 (.30-5
CD3/CD5616þ/CD159aþ (NK cell activation) 1.60 (.20-5
Day 30
CD19þ 1.20 (0-21.
CD3þ/CD134þ .60 (0-9.6
CD4þ/CD25þ/CD127 .20 (0-2.3
CD3/CD5616þ/CD69þ (early activated NK cell) .30 (0-2.1
CD3/CD5616þ/CD159aþ 13.80 (.50-2
CD3/CD5616þ/CD314þ (NK cell activation) 5.90 (.60-2
CD3CD5616þ/CD63þ/CD314þ(NK cell activation) .30 (0-3.4
CD16þ/CD56þ/CD3/CD117 (NK cell activation) 9.90 (.70-3
Day 100
CD3þ/CD86þ .2 (0-1.3
CD4þ/CD25þ/CD127 .1 (0-.9)
CD3/CD5616þ/CD63þ/CD314þ .3 (0-6.3
CD16þ/CD56þ/CD3/CD117 8.6 (0-28.
Values are percent of median, with ranges in parentheses.associatedwith increased GVHD [38-40]. The elevation in the
presence of statin without an increased incidence of GVHD
suggests that GVHD is a constellation of many mechanism
and processes and that the abnormality of 1 process may be
offset by the enhancement of another process.
In conclusion, in our phase II studyand in comparisonwith
our matched control patients, we did not observe any added
beneﬁt with atorvastatin as prophylaxis against aGVHD in
matched related allo-HCT. Given the inherent limitations of0) Nonstatin (n ¼ 25) Wilcoxon Test P
26.90) 10.75 (4.7-20.0) .0374
.70) 3.1 (.5-11.2) .0367
6) .3 (.1-.5) .0148
0) 1.0 (0-4.7) <.0001
0) .6 (.2-1.5) .0072
.40) 2.7 (.4-9.7) .0225
.30) 3.4 (.8-8.3) .0003
10) .7 (0-5.8) .0194
0) 3.4 (.2-7.3) .0010
0) .9 (0-3.6) .0010
0) .8 (0-18.9) .0010
8.10) 20.9 (1.3-48.3) .0220
8.60) 15.1 (2.1-39.3) .0021
0) 2.7 (.3-17.6) <.0001
8.20) 21.6 (3.9-47.8) .0009
) .5 (.1-1.3) .0158
.8 (.1-1.8) .0002
) 1.9 (.2-14.8) .0003
8) 11.5 (6.6-51.3) .0660
Y.A. Efebera et al. / Biol Blood Marrow Transplant 22 (2016) 71e79 79single-institution aGVHD prophylaxis studies, it seems pru-
dent that trials evaluating novel strategies to prevent aGVHD
should be adequately controlled, blinded if possible, and
involve multiple sites at an early phase of development.
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